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ABSTRACT: A copper-catalyzed procedure enabling dynamic 
carbon isotope exchange is described. Utilizing the universal 
precursor [14C]CO2, this protocol allows to insert, in one single 
step, the desired carbon tag into carboxylic acids with no need of 
structural modifications. Reducing synthetic costs and limiting the 
generation of radioactive waste, this procedure will facilitate the 
access to carboxylic acids containing drugs and accelerate early 
14C-based ADME studies supporting drug development. 
As part of drug discovery and development process, a full under-
standing of the fate of drug candidates is strictly required by most 
drug regulatory agencies (FDA, EMA) for marketing applica-
tions.1,2 The direct and traceless incorporation of a mass or radio-
active tag, with no significant structural modifications, is of criti-
cal importance to follow the fate of the drug candidate, when 
administered to humans and animals. To date, the most effective 
and precise method to detect and quantify drugs and their metabo-
lites both in vivo and in vitro relies on the introduction of isotopic 
labels.3 Because of their ubiquitous presence in organic com-
pounds, carbon and hydrogen isotopes are unique tools to eluci-
date the absorption, distribution, metabolism, excretion (ADME) 
of the drug candidate.4,5 For human ADME studies and reactive 
metabolite screens, the use of carbon-14 (14C) over tritium (3H) 
isotopes is generally preferred to circumvent the loss of label due 
to the more rapid hydroxylation and exchange reactions in 
tritiated compounds, while featuring minimal isotope effects.6 The 
insertion of a carbon tag into organic molecules relies on the use 
14C-carbon dioxide (CO2),
7 the universal precursor for all 14C 
labeled compounds; yet, a poorly reactive and remarkably stable 
gas.8 Incorporation of 14C usually leans on strong nucleophiles, 
such as the carboxylation of organolithium and Grignard reagents 
with CO2. This class of reactions, originally developed more than 
100 years ago,9 is often not suitable to address modern challenges 
in radiochemistry and requires early installation of the carbon tag, 
because of functional group incompatibility.10 The hurdles in-
volved in achieving late-stage carbon labeling of functionalized 
organic molecules and pharmaceuticals still represents a major 
challenge.11 Recent developments have mainly been focused on 
late-stage labeling with [14C]CO2 and the secondary building 
block K[14C]CN.12,13 Nevertheless, both strategies require the 
multistep synthesis of elaborated precursors, are limited to specif-
ic structures and lack of generality. An additional challenge to be 
considered is the stoichiometry of the reactions which must be 
reversed compared to the synthesis of the unlabeled materials, as 
the most precious reagent in the radiochemical reaction is 
[14C]CO2. While the emergence of hydrogen isotope exchange 
(HIE) methodologies for the direct insertion of deuterium and 
tritium into drugs has found widespread application in the phar-
maceutical industry,14,15,16  the large majority of carbon-13 and 
carbon-14 labeled pharmaceuticals are still synthesized in multi-
step procedures.17 Besides being time consuming, these proce-
dures generate large amounts of radioactive waste, thus incre-
menting the overall cost of the radiolabeling. The development of 
selective carbon isotope exchange (CIE) reactions would enable 
the synthesis of labeled compounds in a single operation without 
the need for precursors design and synthesis. Such processes 
would be particularly attractive for the pharmaceutical and agro-
chemical industry (Figure 1A). Carboxylic acids are highly abun-
dant functional groups, commonly present in many major drug 
classes, including nonsteroidal anti-inflammatory drugs 
(NSAIDs), diuretics, anti-tumor agents and antibiotics.18 The 
development of carbon isotope exchange procedure on carboxylic 
acid derivatives with CO2 would be highly beneficial for radio-
labeling. 
In nature, the γ-resorcylate decarboxylase (γ-RSD) catalyzes the 
reversible decarboxylation of γ-resorcylate to resorcinol (1,3-
dihydroxybenzene) and CO2, at a zinc active site (Figure 1B).
19,20 
This biochemical transformation inspired us to adopt an analo-
gous approach for the carbon isotopic exchange of carboxylic 
acids (Figure 1D). Decarboxylative cross coupling reactions have 
recently emerged as a method of choice for carbon-carbon bond 
formation. 21 Aromatic carboxylates were shown to undergo ther-
mal carbon dioxide extrusion to generate a highly reactive aryl-
metal species, in the presence of copper or silver salts. In the 
presence of a co-catalyst (i.e. Pd) a rapid transmetallation could 
take place and yield high value carbon-carbon bonds. 22 We rea-
soned that, instead of trapping the aryl-metal species II with an 
appropriate co-catalyst, this intermediate could react with a la-
beled source of CO2 to yield labeled products, through a new CIE 
reaction (Figure 2A). We anticipated that the choice of the metal 
catalyst and the ancillary ligand would heavily influence the 
thermodynamics of the process as well as the competing proto-
decarboxylation of aryl-metal intermediate. In particular, the 
higher reactivity of aryl-metal species II compared to the carbox-
ylate I, as shown by the relative pKa of o-nitrobenzene and the 
corresponding carboxylic acid derivative, should require careful 
consideration and delicate balance. Because copper is an active 
decarboxylation catalyst, able to minimize proto-decarboxylation 
in cross-coupling reactions, we postulated that copper complexes 
could be active catalyst in a CIE reaction.23
  
Figure 1: Catalytic reaction design. (A) Carbon labeling technologies for the insertion of the isotope into pharmaceutically relevant mole-
cules. Light and dark blue circles represent the positions of isotopically labeled C(sp2) with CIE and linear multi step procedures, respec-
tively. (B) Enzymatic reversible decarboxylation of γ-resorcylate to resorcinol. (C) Hurdles to overcome in the routine synthesis of carbon-
14 labeled compounds. (D) Proposed hypothesis for the mechanism of the dynamic CIE. 
 
To test our hypothesis and identify systems capable of mediating 
CIE in carboxylic acids, 2-nitrobenzoic acid was selected as a 
model substrate, the electron withdrawing substituent in ortho 
position favoring a milder decarboxylation step.24 The cesium salt 
of the corresponding acid was utilized to limit a possible proto-
decarboxylation. Catalyst evaluation was initially conducted with 
[13C]CO2 gas, as a convenient and readily handled [
14C]CO2 
surrogate. All of the reactions were conducted under standard 
conditions employing 20 mol% of copper salt, 20 mol% of ligand 
in NMP and DMSO with 3 equivalents of [13C]CO2 at 150 °C. 
The extent of isotopic exchange was determined after 2 hours 
using mass spectroscopy. Selected results from our screening 
experiments are summarized in the supporting information (Table 
S1 to S6). After evaluating a variety of phosphines, NHCs and 
multi-dentate nitrogen ligands, the proof-of-concept was obtained 
in presence of tetramethylethylenediamine (TMEDA, see SI) and 
[13C]2 could be isolated in 21% isotopic enrichment (IE), albeit 
only trace amounts of material could be isolated due to parasitic 
proto-decarboxylation. Surprisingly, a variety of ligands common-
ly utilized in copper-catalyzed decarboxylative cross coupling, 
such as bipyridines were poorly effective in CIE (see Table S2). 
After extensive optimization, we found that ligand L1, featuring a 
bisoxazoline scaffold, enabled the formation of [13C]2 in 75% IE, 
the highest possible enrichment at equilibrium.25  
With the optimized conditions in hand, we sought to examine the 
scope of the CIE protocol with a library of aryl carboxylic acids. 
For the labeling of these substrates (Figure 3), the best conditions 
were found to be substrate-dependent, given a choice of two 
ligands (L1 and L2) and two solvents (DMSO and NMP/DMSO 
as a 4:1 mixture). As expected, the use of carboxylate salts was 
crucial to limit proto-decarboxylation. 
The presence of methyl substituents on the ortho-nitro carbox-
ylates (3-5) did not affect much the reactivity, though a slight 
decrease of the IE was observed when the substituent is in ortho 
([13C]6, 23% IE), as the presence of additional steric hindrance 
results in the decrease of the coordination of the carboxylate to the 
metal center (Figure 3).26 
 
 
Figure 2: Reaction development. (A) Proposed catalytic cycle 
for the CIE protocol. (B) The colored circles (blue or green) and 
numbers denote the positions of the carbon atoms labeled and the 
percent incorporation of the carbon isotope, respectively. DMSO, 
dimethyl sulfoxide.  
 
Stronger electron-donating methoxy groups were well tolerated 
and 13C enriched products [13C]7-9 were obtained in 39% to 64% 
IE. While the presence of iodo and bromo substituents is not 
suitable under the applied reaction conditions, products [13C]10, 
[13C]11 and [13C]12 bearing a m-chlorine, p-chlorine and m-
fluorine were isolated with excellent IE (66%, 59%, 70%). The 
presence of a nitro substituent in meta position was detrimental to 
the reactivity and only unlabeled material was recovered, under 
standard conditions.  
 
  
Figure 3: Cu-catalyzed carbon-13 labeling of representative arenes, heteroarenes and pharmaceutical compounds. The green col-
ored circles and numbers denote the positions of the carbon atoms labeled and the percent incorporation of the carbon-13 isotope, respec-
tively. DMSO, dimethyl sulfoxide. Unless otherwise stated, L1 was utilized. a reaction temperature 190 °C. b L2 was utilized. 
The reactivity could be partially restored by increasing the tem-
perature to 190 °C, and product [13C]13 was isolated with 30% 
IE. The importance of the ortho substituent effect is highlighted in 
substrate 14, where the presence of the o-methyl allows the isola-
tion of [13C]14 in 48% IE, without need of higher temperature. 
Substrates [13C]15 and [13C]16 bearing a nitro substituent in para 
position were isolated with 14% and 15% IE, respectively. Other 
substituents than the nitro group are effective under CIE protocol, 
however the weaker coordinating fluorine group in [13C]17, trans-
lated in a reduction of enrichment (31% IE). On the other hand, 
the use of 1-methoxy naphthalene core [13C]18 gave an interesting 
IE of 39%. Current limitations of the procedure are the presence 
of sole electrodonating methoxy substituents and substrates bear-
ing labile protons which are unproductive or undergo proto-
decarboxylation (see SI for details). 
To test the relevance of this novel CIE procedure, the labeling of 
important substructures in pharmaceuticals was tested. They 
include nitrogen-, oxygen- and sulphur-containing heteroarenes 
(19-27). In particular, methylthiazole [13C]21, benzofuranes- 
[13C]24-25 and indole-2-carboxylates [13C]23 were obtained in 43 
to 65% IE. Chromone and coumarine carboxylate derivatives 
[13C]26-27 were labeled in 29 and 27% IE, respectively. Pharma-
ceutically relevant compounds 28-31 were labeled in a single step 
using the CIE procedure with good IE (Figure 3). 
A series of representative, commercially available pharmaceuti-
cals and drug precursors were then labeled using [14C]CO2, to 
 evaluate the utility of the copper-catalyzed CIE over existing 
multistep methods (Figure 4A). The results were in good agree-
ment with those obtained using stable carbon-13 isotope and did 
not require any further protocol optimization (Figure 3). 2-
Nitrobenzoic acid 2, a synthetic precursor of antipruritic drug 
crotamitone previously labeled with 14C in four steps from 
[14C]CO2,
27
 was obtained by means of CIE with a high molar 
activity of 1506 MBq mmol-1 (Figure 4), meeting previously 
described requirements for use in preclinical candidate selection 
studies.28 Probenecid 29 was labeled in one single step from 
[14C]CO2 with a molar activity of 923 MBq mmol
-1, more three 
times higher than what previous reported by Ellsworth and co-
workers for metabolic disposition studies.29 Fluoroquinolone 
antibiotic flumequine 30 was successfully labeled on the carbox-
ylic acid, which is essential for the pharmacological activity and 
metabolically stable,30 with a molar activity of 1076 MBq mmol-1. 
The preparation of [14C]30 had previously involved a sequence of 
10 linear steps from [14C]CO2.
31 The current CIE procedure has 
the advantage of reducing dramatically the generation of radioac-
tive waste, which are extremely polluting and expensive to dis-
pose of. The 14C labeling of benzofuran-2-carboxylic acid, syn-
thetic precursor of neural nicotinic acetylcholine receptor agonist 
bradanicline, and febuxostat proceeded with good incorporation 
of the carbon tag.  
 
Figure 4: Cu-catalyzed carbon-14 labeling of pharmaceutical 
relevant molecules. (A) Reaction conditions as follows: 20 mol% 
catalyst and ligand loading, see supporting information for de-
tailed experimental procedures. (B) Comparison with multi step 
methods previously reported in the literature. The colored circles 
(dark or light blue) and numbers denote the positions of the car-
bon atoms labeled and the percent incorporation of the carbon 
isotope, respectively. Molar activities for each compound are 
expressed in MBq mmol-1. 
Radiolabeled compounds [14C]24 and [14C]31 were obtained with 
molar activities of 1080 and 1254 MBq mmol-1, in line with val-
ues acceptable for ADME studies. It is worth noting that com-
pared to traditional multi-step procedures the current methodology 
shows a high degree of chemoselectivity, and is compatible with 
the presence of electrophilic moieties such as nitriles, ketones and 
sulfonamides. 
At this early stage of development, this dynamic carbon isotope 
exchange protocol has already opened up new opportunities for 
the synthesis of carbon labeled drug intermediates and pharma-
ceuticals. Further extensions of the CIE can be expected from 
ligand design and the use of a variety of transition metal catalysts. 
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